Please assess the completion status of the following clinical trial:

Trial Title: Equivalence of Boosted Atazanavir Based Regimens and Currently Effective HAART Regimens

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* HIV positive children with elevated lipid levels~* on stable HAART for at least 3 months (defined to be on the same regimen with viral load \< 1000 for 6 months prior to baseline visit).~* Weight equal to or greater than 25kg~* Able to swallow pills or willing to learn~Exclusion Criteria:~* Patients with underlying hepatitis B or C viral infections~* Previously demonstrated clinically significant hypersensitivity (eg, Stevens-Johnson syndrome, erythema multiforme, or toxic skin eruptions) to any of the components of Reyataz® (atazanavir).~* Taking other medications that are highly dependent on CYP3A or UGT1A1 for clearance~  * Ergot medicines: dihydroergotamine, ergonovine, ergotamine, and methylergonovine such as Cafergot®, Migranal®, D.H.E. 45®, ergotrate maleate, Methergine®, and others (used for migraine headaches).~ * Orap® (pimozide, used for Tourette's disorder).~ * Propulsid® (cisapride, used for certain stomach problems).~ * Triazolam, also known as Halcion® (used for insomnia).~ * Midazolam, also known as Versed® (used for sedation), when taken by mouth.~ * Camptosar® (irinotecan, used for cancer).~ * Crixivan® (indinavir, used for HIV infection).~ * Cholesterol-lowering medicines Mevacor® (lovastatin) or Zocor® (simvastatin).~ * Rifampin (also known as Rimactane®, Rifadin®, Rifater®, or Rifamate®).~ * St. John's wort (Hypericum perforatum), an herbal product sold as a dietary supplement,~ * Viramune® (nevirapine, used for HIV infection).~ * Vfend® (voriconazole).~* Patients with grade 3 or higher elevations in transaminases (\> 10 X ULN)~* Women of Childbearing Potential who are unwilling or unable to use an acceptable method to avoid pregnancy for the entire study period.~* Women who are pregnant or breastfeeding.~* Women with a positive pregnancy test.

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- boosted Atazanavir (Type: EXPERIMENTAL): Boosted Atazanavir was switched for the PI or NNRTI in the patients regimen

Based on this trial design, predict the completion outcome and termination type (if applicable).